您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > AZD1390
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AZD1390
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AZD1390图片
CAS NO:2089288-03-7
规格:≥98%
包装与价格:
包装价格(元)
1mg电议
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 477.57
Formula C27H32FN5O2
CAS No. 2089288-03-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO:> 10mM
Water: N/A
Ethanol: N/A
Chemical Name 7-fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one
Synonyms AZD-1390; AZD1390; AZD 1390
SMILES Code O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
实验参考方法
In Vitro

In vitro activity: AZD1390 is a novel, potent, selective, first-in-class orally bioavailable and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cell assays. It is>10,000-fold more selective over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases. AZD1390 has the ability to cross the blood-brain barrier (BBB) which makes it suitable for the treatment of intracranial malignancies. AZD1390 radiosensitizes glioma and lung cancer cell lines, with p53 mutant glioma cells generally being more radiosensitized than wild type. AZD1390 is now in early clinical development for use as a radiosensitizer in central nervous system malignancies.


Kinase Assay: AZD1390 is a novel, potent, selective, first-in-class orally bioavailable and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cell assays. It is>10,000-fold more selective over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases.


Cell Assay: 3000 Cells are seeded into each well of a 384-well plate in RPMI with 10% fetal bovine serum. After 24 hours, plates are Echo-dosed with a semi-log dose dilution of each compound from a top concentration of 1250 nM. One hour after compound dosing, plates are irradiated with 0, 2.5, or 4 Gy. At 1, 6, 24, and 48 hours after irradiation, plates are fixed by adding a 1:1 volume of 8% PFA directly to the medium to give a final concentration of 4% PFA and incubated for 30 min at room temperature before washing three times with phosphate-buffered saline solution (PBSA).

In VivoAZD1390 displays excellent oral bioavailability in preclinical species (66% in rat and 74% in dog). It can efficiently cross the BBB in non-human primate PET studies. Profound tumor regressions and increased animal survival (>50 days) have been observed in orthotopic xenograft models of brain cancer following just 2 or 4 days combination treatment of AZD1390 with radiotherapy, compared to radiotherapy treatment alone. In in vivo syngeneic and patient-derived glioma as well as orthotopic lung-brain metastatic models, AZD1390 dosed in combination with daily fractions of IR (whole-brain or stereotactic radiotherapy) significantly induces tumor regressions and increased animal survival compared to IR treatment alone. AZD1390 has favorable physical, chemical, PK, and PD properties suitable for clinical applications that require exposures within the central nervous system
Animal model Lung NCI-H2228 xenograft mice model either by implanting into nude mice brains directly (intracranial brain) or injecting into the carotid artery [intracarotid artery (ICA)]
Formulation & Dosage Dissolved in 0.5%(w/v)HPMC, and 0.1%(w/v) Tween 80; 5, 15 and 20 mg/kg; Oral gavage
References Science Advances. 2018, 4(6): eaat1719.